August 2012
-
Nasus Pharma said that data from the first cohort dosed in its Phase 2 clinical study of NS002 epinephrine nasal powder demonstrate greater mean peak plasma concentration and faster time to peak concentration for the… Read more . . .
-
According to DPI specialist Iconovo, the European Patent Office has indicated that it plans to approve the company’s patent application for the ICOpre inhaler platform. In 2024, the FDA indicated that the ICOpre device is… Read more . . .
-
CDMO Kindeva has announced that David Stevens has taken over the role of CEO, effective January 1, 2026. Stevens succeeds Milton Boyer, who will remain a member of the board of directors, the company said. Stevens… Read more . . .
-
US-based OINDP instrument and testing specialist Proveris Scientific has been acquired by Investindustrial, which describes itself as “one of Europe’s leading independent investment groups focused on taking majority or control positions, in quality leading mid-market companies.”… Read more . . .
-
Frazier Life Sciences has launched a new company called AirNexis Therapeutics, which will develop inhaled suspension and dry powder formulations of HSK39004, a dual PDE3/4 inhibitor for the treatment of COPD that it has licensed… Read more . . .
-
Kinaset Therapeutics announced that it has raised $103 million in a Series B financing, with proceeds to be used for development of its KN-002 frevecitinib DPI for the treatment of asthma. The financing was led… Read more . . .
-
Nocion Therapeutics said that it has raised an additional $23 million, expanding a Series B financing that raised $62 million in 2024 for development of the company’s taplucainium DPI for the treatment of chronic cough.… Read more . . .
-
Agomab Therapeutics has announced interim results from a Phase 1 study of AGMB-447 inhaled ALK5 inhibitor that was initiated in 2023. The data from the SAD/MAD portion of the study in 108 healthy participants found… Read more . . .
-
Krystal Biotech has announced results from the highest dose cohort of its Phase 1 CORAL-1 trial of KB407 gene therapy that confirm CFTR expression in 6 of 7 cystic fibrosis patients who received 4 administrations… Read more . . .
-
Pulmocide has announced the termination of the Opera-T Phase 3 study of opelconazole inhalation suspension in patients with invasive pulmonary aspergillosis. According to the company, an interim analysis found that patients receiving opelconazole had poorer… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland